74 results on '"Maciejewski, J P"'
Search Results
2. A novel genetic and morphologic phenotype of ARID2-mediated myelodysplasia
3. Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms
4. Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes
5. Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
6. Genomic determinants of chronic myelomonocytic leukemia
7. Erratum: Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome
8. Clinicopathologic and molecular characterization of myeloid neoplasms with isolated t(6;9)(p23;q34)
9. Deletion of Ptpn1 induces myeloproliferative neoplasm
10. The complexity of interpreting genomic data in patients with acute myeloid leukemia
11. Complete mutational spectrum of the autophagy interactome: a novel class of tumor suppressor genes in myeloid neoplasms
12. Epistasis between TIFAB and miR-146a: neighboring genes in del(5q) myelodysplastic syndrome
13. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
14. Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
15. High prevalence and allele burden-independent prognostic importance of p53 mutations in an inner-city MDS/AML cohort
16. GFI1 as a novel prognostic and therapeutic factor for AML/MDS
17. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia
18. Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia
19. Comprehensive quantitative proteomic profiling of the pharmacodynamic changes induced by MLN4924 in acute myeloid leukemia cells establishes rationale for its combination with azacitidine
20. An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms
21. Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia
22. Genomic patterns associated with hypoplastic compared to hyperplastic myelodysplastic syndromes
23. Erratum: Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells
24. Runx1 repression by histone deacetylation is critical for Setbp1-induced mouse myeloid leukemia development
25. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
26. The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
27. Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells
28. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia
29. PRPF8 defects cause missplicing in myeloid malignancies
30. A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction
31. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry
32. Recurrent genetic defects on chromosome 7q in myeloid neoplasms
33. Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation
34. CSF3R T618I co-occurs with mutations of splicing and epigenetic genes and with a new PIM3 truncated fusion gene in chronic neutrophilic leukemia
35. Alternatively spliced, truncated GCSF receptor promotes leukemogenic properties and sensitivity to JAK inhibition
36. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms
37. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies
38. Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies
39. Activation of the mTOR signaling pathway by L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts
40. Spliceosomal gene mutations are frequent events in the diverse mutational spectrum of chronic myelomonocytic leukemia but largely absent in juvenile myelomonocytic leukemia
41. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders
42. Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion
43. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2V617F mutation
44. CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors
45. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts
46. Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes
47. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia
48. Influence of type of antecedent disorder on outcome of therapy-related AML.
49. Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria
50. Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.